spacer
home > ebr > summer 2017 > acting up
PUBLICATIONS
European Biopharmaceutical Review

Acting Up

On January 4, 1983, President Reagan signed the Orphan Drug Act (ODA) into law with the goal of providing financial and marketing incentives so that private pharmaceutical companies would develop more therapeutics for rare diseases. The benefits offered by the ODA include seven years of marketing exclusivity upon approval, tax credits worth 50% of the cost of human clinical trials and federal research grants to fund the development of orphan drugs.

Today, critics question whether the ODA is being used appropriately by firms. Most of this discussion is centred around the ‘orphan subset’ – a subset of a relatively common disease that a narrowly-targeted therapy might be developed for to qualify as an orphan drug and reap the ODA’s protections and benefits. In February 2017, Senator Chuck Grassley opened an inquiry into potential abuses of ODA by drug sponsor; this inquiry is likely to investigate the practice of ‘salami-slicing’ and how this may contribute to high prices of orphan drugs.

Salami-Slicing


This practice is defined as “artificially subdividing diseases to create subgroups of patients that fall under the orphan drug prevalence threshold”.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Matthew Weinberg is Chief Executive Officer at The Weinberg Group. He guides all strategic issues with management client efforts, emphasising the provision of tactical and operational assistance to technically-oriented entities in areas including R&D, regulatory affairs and quality assurance. Matthew’s assignments have involved development of new products, testimony of the management and economics of scientific enterprises, contract issues and product advancement.

Emily Krulewitz is a Consultant at The Weinberg Group. Her work involves issues related to the development and regulation of therapeutics, medical devices, tobacco products and foods. Emily has experience in the preparation, coordination and compilation of regulatory submissions as well as responding to various legislative challenges through the development of technical reports. She received a bachelor’s degree in chemistry and integrated arts from Northwestern University, US, and a master’s degree in biotechnology from Johns Hopkins University, US.

spacer
Matthew Weinberg
spacer
spacer
spacer
Emily Krulewitz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Announces Success of Integrated Discovery Project with ENYO Pharma

Wilmington, Mass and Lyon, France, Nov. 28, 2017 - Charles River Laboratories International, Inc. (NYSE: CRL) and ENYO Pharma SA today announced the results of a successful collaboration. Together, the companies identified the mode of action of ENYO Pharma’s lead preclinical chemical series, EYP002, using Charles River’s newly acquired, molecular target identification tool: Capture Compound Mass Spectrometry (CCMS) technology.
More info >>

White Papers

Cartridge Based Drug Delivery System

Weibel CDS AG

Cartridge based drug delivery systems small and easy to use? This question is discussed in this article by Ludwig Weibel, CEO and Hans Peter Manser, Business Director of Weibel CDS AG. A novel and innovative approach is presented offering patients numerous advantages making their life easier, saving time and avoiding needle stick injuries. Safer, easier and faster drug delivery – Weibel CDS AG, Switzerland develops and produces innovative, user friendly, application oriented injection systems and devices.
More info >>

 
Industry Events

12th annual Cold Chain Distribution Conference and Exhibition

13-14 December 2017, Copthorne Tara Hotel, London, UK

Responding to the evolution within the industry, SMi is proud to announce the return of its leading 12th annual Cold Chain Distribution event. Returning to London in December, this year's event will remain at the forefront of innovation
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement